## Simavita

## **ASX ANNOUNCEMENT**

## Cleansing Notice

For Immediate Release: 9 October, 2018

**Sydney, Australia** – Simavita Limited (the "**Company**") (ASX: SVA) refers to the Appendix 3B released today for the issue of 68,499,999 CHESS Depositary Interests (**CDIs**).

The Company notifies the ASX under section 708A[5](e) of the Corporations Act (the Act) that:

- 1. the Company issued the CDIs without disclosure to the investors under Part 6D.2 of the Act;
- 2. as at 9 October, 2018, the Company has complied with the provisions of Chapter 2M of the Act as they apply to the Company, and section 674 of the Act; and
- 3. as at 9 October, 2018, there is no information:
  - a. that has been excluded from a continuous disclosure notice in accordance with the ASX Listing Rules; and
  - b. that investors and their professional advisers would reasonably require for the purpose of making an informed assessment of:
    - i. the assets and liabilities, financial position and performance, profits and losses and prospects of the Company; or
    - ii. the rights and liabilities attaching to the CDIs.

For further information, please check our website (www.simavita.com) or contact:

Ms Peta Jurd

E: <u>pjurd@simavita.com</u>
T: +61 2 8405 6300

## **About Simavita**

Simavita (ASX: SVA) develops and markets advanced systems associated with smart, wearable and disposable sensors for the global diaper manufacturing industry and also for the aged and disabled care markets. This industry currently generates approximately USD 64bn in annual revenues.

Simavita offers an extremely low cost sensor platform technology for everyday use in all adult and infant diapers. AlertPLUS $^{\text{TM}}$  is incorporated into the diaper manufacturing process and connects to your smart device via an App. The platform is ready for partnering with major international diaper manufacturers.

Simavita's technology portfolio also includes AssessPLUS<sup>TM</sup>, an easy to use tablet based product for the assessment of incontinence which delivers a personalised, evidence base incontinence care plan.

With the support of our shareholders, customers and employees, Simavita is absolutely committed to the business at hand; creating a commercially successful and growing corporation. <a href="www.simavita.com">www.simavita.com</a>